Case Study: MN553 Advanced Pharmacology
Unit 9 Case Study
“
This paper addresses a pharmacological management plan for Mr. NX, including consideration of possible contraindications for CAMs, prescriptive, and non-prescriptive recommendations for management of acute pain and other ongoing disease processes, followed by evaluation strategies.
Pharmacological Management Plan
CAMs Contraindicated with Current Prescriptions
CAMs Contraindicated with Diagnoses
Prescription for Back Pain
Changes in Prescribed Drugs
Follow-Up Evaluations
Time-Frame
Strategies for Evaluating Side/Adverse Effects
Strategies for Evaluating Effectiveness
References (examples)
Romm, A. (2011). Overprescribing of antibiotics for children’s upper respiratory infections. Alternative options to consider. Alternative and Complementary Therapies, 17(6), 306–309. Retrieved from http://search.ebscohost.com.lib.kaplan.edu/login.aspx?direct=true&db=rzh&AN=2011411466&site=eds-live
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M.,…Saag, K. G. (2012). Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. In U.S. Department of Health and Human Services, Agency for Health Research and Quality, National Guideline Clearinghouse. Retrieved from http://www.guideline.gov/content.aspx?id=36892&search=rheumatoid+arthritis
